Ampersand Capital Partners has closed its latest healthcare-focused fund, raising $1.5 billion in limited partner commitments. The oversubscribed Ampersand 2026 Limited Partnership marks the firm's twelfth primary fund since 1992, reflecting sustained investor confidence in their specialized investment strategy.

Founded in 1988 and headquartered in Wellesley, Massachusetts, Ampersand targets middle-market companies across North America, Europe, and the Asia-Pacific region. The firm specializes in growth equity investments within the healthcare sector, typically taking majority or minority stakes in businesses generating $10 million to $200 million in revenue with positive EBITDA.

The successful fundraise underscores strong demand for healthcare private equity exposure amid continued sector growth. With $1.5 billion in fresh capital, Ampersand can pursue multiple platform investments and add-on acquisitions across healthcare services, medical devices, and life sciences companies.

This represents Ampersand's largest fund to date and signals robust LP appetite for healthcare growth strategies despite market volatility. The oversubscription suggests investors view the firm's three-decade track record and sector expertise as compelling opportunities in an evolving healthcare landscape.